This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WuXi PharmaTech To Manufacture Ibalizumab For TaiMed Biologics

SHANGHAI and TAIPEI, Aug. 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.  Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors.  This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States.  

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Edward Hu, Chief Operating Officer of WuXi PharmaTech.  "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com.

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases. For more information, please visit http://www.taimedbiologics.com.

WuXi PharmaTech

Aaron Shi (for the media)Tel: +86-21-5046 Email: Aaron_Shi@wuxiapptec.com

Ronald Aldridge (for investors)Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com

TaiMed Biologics

James N. Chang, PhDChief Executive Officer, TaiMed Biologics

Tel: 1-949-769-6543 ( USA), 886-2-2655-8031 ( Taiwan)Email: jchang@taimedbiologics.com

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs